Literature DB >> 17060111

Assessing the natural course of diabetic retinopathy: a population-based study in Kinmen, Taiwan.

Tao-Hsin Tung1, Shih-Jen Chen, Hui-Chuan Shih, Pesus Chou, An-Fei Li, Mong-Ping Shyong, Feng-Li Lee, Jorn-Hon Liu.   

Abstract

PURPOSE: To explore the natural course of diabetic retinopathy among type 2 diabetics using the indirect ophthalmoscope and single-field fundus photographs in Kinmen, Taiwan.
METHODS: A screening program for diabetic retinopathy was carried out by a panel of ophthalmologists, who employed the ophthalmoscope and 45-degree retinal color photographs to examine the fundus after pupil dilation. Screening, which was conducted between 1999 and 2002, involved 971 patients diagnosed with type 2 diabetes. A multi-state Markov model was used to assess the natural course of diabetic retinopathy among type 2 diabetics.
RESULTS: Among the 725 diabetes patients who attended at least two ophthalmological fundus check-ups and were screened, the overall response rate was about 75%. The mean duration of the disease states mild nonproliferative diabetic retinopathy, moderate nonproliferative diabetic retinopathy, severe nonproliferative diabetic retinopathy, and proliferative diabetic retinopathy were 4.05 [95% confidence interval (CI): 3.28-5.32], 4.18 (95% CI: 3.18-6.06), 2.52 (95% CI: 1.78-4.27), and 4.22 (95% CI: 2.88-7.81) years, respectively. Compared to controls, the incidence of blindness reduction for annual, biennial, 3-year, 4-year, and 5-year screenings of diabetic retinopathy were approximately 94.4% (95% CI: 91.6%-96.3%), 83.9% (95% CI: 83.6%-84.2%), 70.2% (95% CI: 69.8%-70.7%), 57.2% (95% CI: 56.7%-57.7%), and 45.6% (95% CI: 45.0%-46.1%), respectively.
CONCLUSIONS: In conclusion, the average time for the development of diabetic retinopathy from nonexistence to blindness was approximately 26.5 years. The present recommendation for annual screening in type 2 diabetics with nonproliferative diabetic retinopathy should be retained only for the mild form, not for the moderate or severe forms.

Entities:  

Mesh:

Year:  2006        PMID: 17060111     DOI: 10.1080/09286580600826637

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  10 in total

1.  Assessing type I error and power of multistate Markov models for panel data-A simulation study.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  Commun Stat Simul Comput       Date:  2016-09-23       Impact factor: 1.118

2.  Using Markov Chains to predict the natural progression of diabetic retinopathy.

Authors:  Priyanka Srikanth
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

3.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes.

Authors:  Ronald Klein; Michael D Knudtson; Kristine E Lee; Ronald Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2008-11       Impact factor: 12.079

4.  Factors Associated with Prevalent Diabetic Retinopathy in Chinese Americans: The Chinese American Eye Study.

Authors:  Douglas A Stram; Xuejuan Jiang; Rohit Varma; Mina Torres; Bruce S Burkemper; Farzana Choudhury; Ronald Klein; W James Gauderman; Roberta McKean-Cowdin
Journal:  Ophthalmol Retina       Date:  2017-08-16

5.  Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea.

Authors:  Jae Seung Yun; Tae Seok Lim; Seon Ah Cha; Yu Bae Ahn; Ki Ho Song; Jin A Choi; Jinwoo Kwon; Donghyun Jee; Yang Kyung Cho; Yong Moon Park; Seung Hyun Ko
Journal:  Diabetes Metab J       Date:  2016-10-05       Impact factor: 5.376

6.  Determining Risk Factors That Affect Progression in Patients with Nonproliferative Diabetic Retinopathy.

Authors:  Dalbert J Chen; Jacky C Kuo; Alex J Wright; Alice Z Chuang; Wenyaw Chan; Robert M Feldman; Eric L Crowell
Journal:  J Ophthalmol       Date:  2021-11-30       Impact factor: 1.909

7.  Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China.

Authors:  Xiao-Mei Huang; Bo-Fan Yang; Wen-Lin Zheng; Qun Liu; Fan Xiao; Pei-Wen Ouyang; Mei-Jun Li; Xiu-Yun Li; Jing Meng; Tian-Tian Zhang; Yu-Hong Cui; Hong-Wei Pan
Journal:  BMC Health Serv Res       Date:  2022-02-25       Impact factor: 2.655

8.  Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan.

Authors:  Tao-Hsin Tung; Hui-Chuan Shih; Shih-Jen Chen; Pesus Chou; Chi-Ming Liu; Jorn-Hon Liu
Journal:  J Epidemiol       Date:  2008-09-08       Impact factor: 3.211

9.  A community-based study of the willingness to pay associated with screening for diabetic retinopathy among type 2 diabetes in Kinmen, Taiwan.

Authors:  Hui-Chuan Shih; Pesus Chou; Shih-Jen Chen; Jorn-Hon Liu; Fenq-Li Lee; Chi-Ming Liu; Tao-Hsin Tung
Journal:  J Epidemiol       Date:  2007-11       Impact factor: 3.211

10.  Progression of Diabetic Retinopathy and Declining Renal Function in Patients with Type 2 Diabetes.

Authors:  AJin Cho; Hayne Cho Park; Young-Ki Lee; Young Joo Shin; So Hyun Bae; Hakyoung Kim
Journal:  J Diabetes Res       Date:  2020-07-26       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.